RESUMO

CDKN2A is a tumor suppressor gene critical in the cell cycle regulation. Little is known regarding the role of CDKN2A methylation in the pathogenesis of Burkitt lymphoma (BL). CDKN2A methylation was investigated using pyrosequencing in 51 tumor samples. p16(INK4a) mRNA and protein levels were measured using real-time PCR and immunohistochemistry, respectively. CDKN2A methylation was detectable in 72% cases. Nuclear expression of p16(INK4a) was not detected in 41% cases. There was an association between methylation and absence of CDKN2A mRNA (P=0.003). In conclusion, CDKN2A methylation occurs at a high frequency suggesting a role in BL pathogenesis and potential therapeutic implications.

Assuntos

Linfoma de Burkitt/metabolismo , Inibidor p16 de Quinase Dependente de Ciclina/biossíntese , Metilação de DNA , DNA de Neoplasias/metabolismo , Regulação Neoplásica da Expressão Gênica , RNA Mensageiro/biossíntese , RNA Neoplásico/biossíntese , Adolescente , Linfoma de Burkitt/genética , Linhagem Celular Tumoral , Pré-Escolar , Inibidor p16 de Quinase Dependente de Ciclina/genética , DNA de Neoplasias/genética , Feminino , Humanos , Masculino , RNA Mensageiro/genética , RNA Neoplásico/genética